Esther Toes-Zoutendijk1, Arthur I Kooyker2, Evelien Dekker3, Manon C W Spaander4, Annemieke W J Opstal-van Winden5, Christian Ramakers6, Maaike Buskermolen5, Anneke J van Vuuren4, Ernst J Kuipers4, Folkert J van Kemenade7, Marie-Louise F Velthuysen7, Maarten G J Thomeer8, Harriët van Veldhuizen9, Marjolein van Ballegooijen5, Iris D Nagtegaal10, Harry J de Koning5, Monique E van Leerdam11, Iris Lansdorp-Vogelaar5. 1. Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. Electronic address: e.toes-zoutendijk@erasmusmc.nl. 2. Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Gastroenterology and Hepatology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Gastroenterology and Hepatology, Academic Medical Center, Academic University Medical Centers, Amsterdam, the Netherlands. 4. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 5. Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 6. Department of Clinical Chemistry, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 7. Department of Pathology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 8. Department of Radiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 9. Department of Quality Improvement, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 10. Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. 11. Department of Gastroenterology and Hepatology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
BACKGROUND & AIMS: We evaluated the incidence of interval cancers between the first and second rounds of colorectal cancer (CRC) screening with the FOB-Gold fecal immunochemical test (FIT), and the effects of different cutoff values and patient sex and age. METHODS: We collected data from participants in a population-based CRC screening program in the Netherlands who had a negative result from a first-round of FIT screening. We calculated the cumulative incidence of interval cancer after a negative result from a FIT and the sensitivity of the FIT for detection of CRC at a low (15 μg Hb/g feces) and high (47 μg Hb/g feces) cutoff value. RESULTS: Among the 485,112 participants with a negative result from a FIT, 544 interval cancers were detected; 126 were in the 111,800 participants with negative results from a FIT with the low cutoff value and 418 were in the 373,312 FIT participants with negative results from a FIT with the high cutoff value. The mean age of participants tested with the low cutoff value was 72.0 years and the mean age of participants tested the high cutoff value was 66.7 years. The age-adjusted 2-year cumulative incidence of interval cancer after a negative result from a FIT were 9.5 per 10,000 persons at the low cutoff value vs 13.8 per 10,000 persons at the high cutoff value (P < .005). The age-adjusted sensitivity of the FIT for CRC were 90.5% for the low cutoff value vs 82.9% for the high cutoff (P < .0001). The FIT identified men with CRC with 87.4% sensitivity and women with CRC with 82.6% sensitivity (P < .001). CONCLUSIONS: In an analysis of data from a FIT population-based screening program in the Netherlands, we found that incidence of interval CRC after a negative result from a FIT to be low. Although the sensitivity of detection of CRC decreased with a higher FIT cutoff value, it remained above 80%.
BACKGROUND & AIMS: We evaluated the incidence of interval cancers between the first and second rounds of colorectal cancer (CRC) screening with the FOB-Gold fecal immunochemical test (FIT), and the effects of different cutoff values and patient sex and age. METHODS: We collected data from participants in a population-based CRC screening program in the Netherlands who had a negative result from a first-round of FIT screening. We calculated the cumulative incidence of interval cancer after a negative result from a FIT and the sensitivity of the FIT for detection of CRC at a low (15 μg Hb/g feces) and high (47 μg Hb/g feces) cutoff value. RESULTS: Among the 485,112 participants with a negative result from a FIT, 544 interval cancers were detected; 126 were in the 111,800 participants with negative results from a FIT with the low cutoff value and 418 were in the 373,312 FIT participants with negative results from a FIT with the high cutoff value. The mean age of participants tested with the low cutoff value was 72.0 years and the mean age of participants tested the high cutoff value was 66.7 years. The age-adjusted 2-year cumulative incidence of interval cancer after a negative result from a FIT were 9.5 per 10,000 persons at the low cutoff value vs 13.8 per 10,000 persons at the high cutoff value (P < .005). The age-adjusted sensitivity of the FIT for CRC were 90.5% for the low cutoff value vs 82.9% for the high cutoff (P < .0001). The FIT identified men with CRC with 87.4% sensitivity and women with CRC with 82.6% sensitivity (P < .001). CONCLUSIONS: In an analysis of data from a FIT population-based screening program in the Netherlands, we found that incidence of interval CRC after a negative result from a FIT to be low. Although the sensitivity of detection of CRC decreased with a higher FIT cutoff value, it remained above 80%.
Authors: Su Young Kim; Hyun-Soo Kim; Yun Tae Kim; Jung Kuk Lee; Hong Jun Park; Hee Man Kim; Dae Ryoung Kang Journal: Clin Transl Gastroenterol Date: 2021-04-30 Impact factor: 4.396
Authors: Shuping J Li; Tara Seedher; Linda D Sharples; Sally C Benton; Christopher Mathews; Rhian Gabe; Peter Sasieni; Stephen W Duffy Journal: Br J Cancer Date: 2022-08-17 Impact factor: 9.075
Authors: Nina C A Vermeer; Maxime J M van der Valk; Heleen S Snijders; Hans F A Vasen; Arthur Gerritsen van der Hoop; Onno R Guicherit; Gerrit-Jan Liefers; Cornelis J H van de Velde; Anne M Stiggelbout; Koen C M J Peeters Journal: Psychooncology Date: 2020-04-14 Impact factor: 3.894